COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Financials & Filings

Filing date	Description	Form	Filing Group	Issuer	View
Jan 31, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000022.pdf 0001103021-20-000022.rtf
Jan 23, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000012.pdf 0001103021-20-000012.rtf
Jan 17, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000010.pdf 0001103021-20-000010.rtf
Jan 13, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000008.pdf 0001103021-20-000008.rtf 0001103021-20-000008.xls
Jan 09, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000006.pdf 0001103021-20-000006.rtf
Jan 06, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000004.pdf 0001103021-20-000004.rtf
Jan 03, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000002.pdf 0001103021-20-000002.rtf
Dec 31, 2019	Amendment to a previously filed 4	4/A	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-19-000061.pdf 0001103021-19-000061.rtf
Dec 30, 2019	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-19-000059.pdf 0001103021-19-000059.rtf
Dec 23, 2019	An amendment to a SC 13D filing	SC 13D/A	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0000919574-19-007788.pdf 0000919574-19-007788.rtf 0000919574-19-007788.xls

Data provided by Kaleidoscope.

Recent BDSI News

BioDelivery Sciences to Present at Two Upcoming Investor Conferences May 29, 2020

RALEIGH, N.C. , May 29, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive ...

BioDelivery Sciences Appoints Jeff Bailey Interim CEO May 11, 2020

RALEIGH, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey A. ...

BioDelivery Sciences Reports Strong Q1 2020 Results May 7, 2020

First Quarter Total Company Net Sales Increased 94% versus Prior Year to $38.3 Million First Quarter BELBUCA® Net Sales Increased 79% versus Prior Year to $33.5 Million Conference Call and Webcast Scheduled for 4:30 PM EST Today RALEIGH, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now